378 related articles for article (PubMed ID: 22838399)
1. Hurdles in tissue engineering/regenerative medicine product commercialization: a pilot survey of governmental funding agencies and the financial industry.
Bertram TA; Tentoff E; Johnson PC; Tawil B; Van Dyke M; Hellman KB
Tissue Eng Part A; 2012 Nov; 18(21-22):2187-94. PubMed ID: 22838399
[TBL] [Abstract][Full Text] [Related]
2. Financial influence on global risks of zoonotic emerging and re-emerging diseases: an integrative analysis.
Galaz V; Rocha J; Sánchez-García PA; Dauriach A; Roukny T; S Gaard J Rgensen P
Lancet Planet Health; 2023 Dec; 7(12):e951-e962. PubMed ID: 38056966
[TBL] [Abstract][Full Text] [Related]
3. Cell and gene therapy investment: evolution and future outlook on investor perspectives.
Kunze-Küllmer M; Goonewardene A; Kili S; Theoharis S; Rivers P
Cytotherapy; 2024 Jul; 26(7):672-680. PubMed ID: 38483363
[TBL] [Abstract][Full Text] [Related]
4. Moving research to patient applications through commercialization: understanding and evaluating the role of intellectual property.
Patino RM
J Am Assoc Lab Anim Sci; 2010 Mar; 49(2):147-54. PubMed ID: 20353687
[TBL] [Abstract][Full Text] [Related]
5. Will the negative psychological perceptions of investors reduce platform liquidity? Evidence from China's online loans.
Qin Z; Liu T; Yu X; Yang L
PLoS One; 2023; 18(10):e0292158. PubMed ID: 37816040
[TBL] [Abstract][Full Text] [Related]
6. Regenerative medicine: the emergence of an industry.
Nerem RM
J R Soc Interface; 2010 Dec; 7 Suppl 6(Suppl 6):S771-5. PubMed ID: 20843840
[TBL] [Abstract][Full Text] [Related]
7. Meeting the need for regenerative therapies I: target-based incidence and its relationship to U.S. spending, productivity, and innovation.
Parenteau N; Hardin-Young J; Shannon W; Cantini P; Russell A
Tissue Eng Part B Rev; 2012 Apr; 18(2):139-54. PubMed ID: 22044424
[TBL] [Abstract][Full Text] [Related]
8. Pension and state funds dominating biomedical R&D investment: fiduciary duty and public health.
Roller S
Global Health; 2019 Nov; 15(1):55. PubMed ID: 31690328
[TBL] [Abstract][Full Text] [Related]
9. Venture capital investment in urology, 2011 to mid-2021.
Briggs LG; Uppal N; Langbein B; Bhojani N; Kathrins M; Trinh QD
Can J Urol; 2023 Oct; 30(5):11659-11667. PubMed ID: 37838992
[TBL] [Abstract][Full Text] [Related]
10. Public welfare agenda or corporate research agenda?
Singh A; Singh S
Mens Sana Monogr; 2005 Mar; 3(1):41-80. PubMed ID: 22679348
[TBL] [Abstract][Full Text] [Related]
11. The connection between academia and industry.
Singh A; Singh S
Mens Sana Monogr; 2005 Mar; 3(1):5-35. PubMed ID: 22679346
[TBL] [Abstract][Full Text] [Related]
12. Do executives' backgrounds matter to IPO investors? Evidence from the life science industry.
Chok J; Qian J
PLoS One; 2013; 8(5):e60911. PubMed ID: 23690920
[TBL] [Abstract][Full Text] [Related]
13. Utilization of foreign investment in the productive service industry in Hubei province, China and its optimization counter-measures.
Zhou Y; Wang Y; Wang Q
PLoS One; 2024; 19(6):e0302494. PubMed ID: 38900766
[TBL] [Abstract][Full Text] [Related]
14. The impact of companies disclosing ESG reports in multiple languages on the enthusiasm of foreign investors for holding shares.
Bao R; Wei L
PLoS One; 2024; 19(3):e0299643. PubMed ID: 38452011
[TBL] [Abstract][Full Text] [Related]
15. The impact of technical efficiency on firms' value: The case of the halal food and beverage industry in selected countries.
Rusmita SA; Zulaikha S; Mazlan NS; Mohd Dali NRSB; Cahyono EF; Ramadhani I
PLoS One; 2023; 18(11):e0286629. PubMed ID: 38011115
[TBL] [Abstract][Full Text] [Related]
16. Investment analysis of the private firm under different financial arrangements in infrastructure projects.
Ding Q; Huang S; Fu G; Wang B
PLoS One; 2024; 19(2):e0287418. PubMed ID: 38363762
[TBL] [Abstract][Full Text] [Related]
17. Risk allocation schemes between public and private sectors in green energy projects.
Fleta-Asín J; Muñoz F
J Environ Manage; 2024 Apr; 357():120650. PubMed ID: 38569262
[TBL] [Abstract][Full Text] [Related]
18. The price of progress: Funding and financing Alzheimer's disease drug development.
Cummings J; Reiber C; Kumar P
Alzheimers Dement (N Y); 2018; 4():330-343. PubMed ID: 30175227
[TBL] [Abstract][Full Text] [Related]
19. Steering the Private Sector in COVID-19 Diagnostic Test Kit Development in South Korea.
Lee S
Front Public Health; 2020; 8():563525. PubMed ID: 33282810
[TBL] [Abstract][Full Text] [Related]
20. Profiting on Crisis: How Predatory Financial Investors Have Worsened Inequality in the Coronavirus Crisis.
Neely MT; Carmichael D
Am Behav Sci; 2021 Nov; 65(12):1649-1670. PubMed ID: 38603051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
